Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02137226 · ClinicalTrials.gov registry record · Phase 3
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 645
- Enrollment target
- 20
- Study locations
NCT02137226 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Boehringer Ingelheim. The registered enrollment target is 645 participants, roughly in line with the 617-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT02137226, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 645 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: The primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the proportion of patients meeting American College of Rheumatology 20% (ACR20) response rate at Week 12 and ACR20 response rate at Week 24 between BI 695501 and US-licensed Humira®. Secondary Objectives: The secondary objectives of this trial are to compare the efficacy, safety and immunogenicity of BI 695501 and US-licensed Humira® in patients with active RA including those undergoing the transition from US-licensed Humira® to BI 695501 after 24 weeks.
Conditions Studied
Interventions
- DRUG BI 695501
- DRUG US-licensed Humira®
Study Locations (20)
California
- TriWest Research Associates, LLC - El Cajon
- Advanced Medical Research, LLC - La Palma
- ProHealth Partners - Long Beach
- The Permanente Medical Group - Santa Clara
- Inland Rheumatology Clinical Trials, Inc. - Upland
- Medvin Clinical Research - Whittier
Florida
- Orthopedic Research Institute - Boynton Beach
- Clinical Research of West Florida, Inc. - Clearwater
- Universal Clinical Research - Coral Gables
- Science and Research Institute, Inc. - Jupiter
- San Marcus Research Clinic, Inc. - Miami
- L&C Professional Medical Research Institute - Miami
Arizona
- Arizona Arthritis and Rheumatology Research, PLLC - Glendale
- Arizona Arthritis and Rheumatology Research, PLLC - Mesa
- Arizona Arthritis and Rheumatology Research, PLLC - Phoenix
- Arizona Arthritis and Rheumatology Research, PLLC - Phoenix
Alabama
- Pinnacle Research Group, LLC - Anniston
- Rheumatology Associates - Birmingham
- Achieve Clinical Research, LLC - Birmingham
Colorado
- Alpine Clinical Research Center - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2015-01-26 |
| Est. Completion | 2016-10-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02137226
The ClinicalTrials.gov registry entry for NCT02137226 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 617-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 2 interventions - of which BI 695501 is the first listed.
NCT02137226 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02137226 about?
NCT02137226 is a clinical study titled "BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis". Primary Objective: The primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the proportion of patients meeting American College of Rheumatology 20% (ACR2...
What is the current status of trial NCT02137226?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 645 participants. The study started on 2015-01-26. Estimated completion is 2016-10-18.
What conditions does trial NCT02137226 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT02137226?
The interventions under investigation include: BI 695501 (DRUG), US-licensed Humira® (DRUG).
Who is sponsoring clinical trial NCT02137226?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02137226 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.